News
Public · Published
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals said adults in England and Wales with Familial Chylomicronaemia Syndrome, a rare metabolic condition, can now get REDEMPLO (plozasiran) on the NHS to lower extremely high triglycerides, a type of fat in the blood, when diet and conventional therapies have not worked well enough.
Published:
Updated:
What happened
Arrowhead Pharmaceuticals said adults in England and Wales with Familial Chylomicronaemia Syndrome, a rare metabolic condition, can now get REDEMPLO (plozasiran) on the NHS to lower extremely high triglycerides, a type of fat in the blood, when diet and conventional therapies have not worked well enough.
Confirmed
Global impact / market context
This gives Arrowhead a funded NHS market in England and Wales for plozasiran, which means the company can earn revenue from a public health system. That revenue may help offset the costs of developing the drug and support future research spending.
Analyst inference
FCS is a rare condition, so the number of patients is small, but treated patients can generate steady revenue per person. NHS funding with a commercial arrangement, meaning a confidential pricing deal, reduces the risk that doctors cannot prescribe the drug because of cost.
Analyst inference
What to watch
- NICE recommended NHS funding for plozasiran in adults with genetically confirmed FCS when diet and conventional triglyceride-lowering therapies have not worked well enough. Confirmed
- Watch how quickly NHS doctors begin prescribing plozasiran, since adoption speed will determine how soon Arrowhead records revenue from England and Wales. Proposed
- Watch whether sales of plozasiran grow enough to cover Arrowhead's research and launch costs, because weak uptake would limit the cash the drug generates. Analyst inference
Evidence
- Original source link unavailable